Skip to main content

Table 2 Patients with use of traditional acute and preventive migraine medications during the 6-month pre-index period, overall and by prior mAb use

From: Treatment patterns for patients initiating novel acute migraine specific medications (nAMSMs) in the context of monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) pathway

 

Overall

N = 78,574

Patients with prior mAb usea

N = 26,656

Patients without prior mAb usea

n = 51,918

Acute migraine medication use, n (%)

59,290 (75.5%)

21,842 (81.9%)

37,448 (72.1%)

 Triptans

36,054 (45.9%)

14,182 (53.2%)

21,872 (42.1%)

 Opioids

29,692 (37.8%)

11,116 (41.7%)

18,576 (35.8%)

 NSAIDs

26,644 (33.9%)

10,118 (38.0%)

16,526 (31.8%)

 Ergots

1,255 (1.6%)

718 (2.7%)

537 (1.0%)

Preventive migraine medication use (n, %)

62,428 (79.5%)

22,378 (84.0%)

40,050 (77.1%)

 Select antidepressant medicationsb

37,753 (48.1%)

14,108 (52.9%)

23,645 (45.5%)

 Select anticonvulsant medicationsc

34,930 (44.5%)

13,197 (49.5%)

21,733 (41.9%)

 Select antihypertensive medicationsd

24,751 (31.5%)

9,243 (34.7%)

15,508 (29.9%)

 Other medications that prevent migrainese

12,494 (15.9%)

5,353 (20.1%)

7,141 (13.8%)

 Select botulinum toxin medicationsf

9,669 (12.3%)

3,378 (12.7%)

6,291 (12.1%)

  1. mAb monoclonal antibody, NSAIDs non-steroidal anti-inflammatory drugs
  2. aPrior mAb (erenumab, galcanezumab, fremanezumab) use was evaluated during the 6-month period prior to the index date
  3. bSelect antidepressant medications included oral formulations of duloxetine, desvenlafaxine, venlafaxine, amitriptyline, desipramine, doxepin, imipramine, nortriptyline, protriptyline, clomipramine, escitalopram, citalopram, sertraline, and mirtazapine
  4. cSelect anticonvulsant medications included oral formulations of carbamazepine, gabapentin, levetiracetam, pregabalin, topiramate, valproate sodium, valproic acid, divalproex sodium, and zonisamide
  5. dSelect antihypertensive medications included oral formulations (unless noted otherwise) of atenolol, bisoprolol, metoprolol, nadolol, nebivolol, pindolol, propranolol, timolol, verapamil, candesartan, clonidine (oral and transdermal patch formulations), lisinopril, and olmesartan
  6. eOther medications that prevent migraines included oral formulations of carisoprodol, cyproheptadine, guanfacine, memantine, methysergide, milnacipran, and tizanidine
  7. fSelect botulinum toxin medications included abobotulinumtoxinA injection, incobotulinumtoxinA injection, onabotulinumtoxinA injection, and rimabotulinumtoxinB injection. These medications were identified with National Drug Codes (NDCs) on prescription claims and Healthcare Procedural Classification System (HCPCS) codes on medical claims
Back to article page

The Journal of Headache and Pain

ISSN: 1129-2377

Contact us